Circulating tumour cells to drive the use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer

BACKGROUND: Guidelines recommend neoadjuvant chemotherapy (NAC) for the treatment of nonmetastatic muscle-invasive bladder cancer (MIBC). NAC is, however, underutilized in practice because of its associated limited overall survival (OS) benefit and significant treatment-related toxicity. We hypothes...

Descripción completa

Detalles Bibliográficos
Autores principales: Beije, N., de Kruijff, I.E., de Jong, J.J., Klaver, S.O., de Vries, P., Jacobs, R.A.L., Somford, D.M., te Slaa, E., van der Heijden, A.G., Alfred Witjes, J., Fossion, L.M.C.L., Boevé, E.R., van der Hoeven, J., van Melick, H.H.E., Wijburg, C.J., Bickerstaffe, H., Martens, J.W.M., de Wit, R., Kraan, J., Sleijfer, S., Boormans, J.L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058916/
https://www.ncbi.nlm.nih.gov/pubmed/35248823
http://dx.doi.org/10.1016/j.esmoop.2022.100416

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058916/
https://www.ncbi.nlm.nih.gov/pubmed/35248823
http://dx.doi.org/10.1016/j.esmoop.2022.100416

Ejemplares similares